Considering that no specific factors are currently able to prospectively predict the best response the patient will achieve, nor for how long it will last, these results suggest that anti-PD1/PD-L1 ICI might be preferably discontinued at tumor progression or unacceptable toxicity, justifying maintenance/durable treatment strategies. This evidence concerns the gene CD274 and neoplasm.